Israpafant
98%
- Product Code: 63502
CAS:
117279-73-9
| Molecular Weight: | 489.074 g./mol | Molecular Formula: | C₂₈H₂₉ClN₄S |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C, airtight, dry |
Product Description:
Israpafant is primarily studied for its potential therapeutic applications in the field of medicine. It is known for its role as a platelet-activating factor (PAF) receptor antagonist, which makes it a candidate for treating conditions related to inflammation and immune response. Research has explored its use in managing asthma, as it may help reduce bronchial hyperresponsiveness and inflammation in the airways. Additionally, Israpafant has been investigated for its potential benefits in treating septic shock, as it can inhibit the effects of PAF, a key mediator in the inflammatory cascade associated with this condition. Its anti-inflammatory properties also suggest possible applications in other inflammatory disorders, though further studies are needed to confirm its efficacy and safety in clinical settings.
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | £1,954.11 |
+
-
|
Israpafant
Israpafant is primarily studied for its potential therapeutic applications in the field of medicine. It is known for its role as a platelet-activating factor (PAF) receptor antagonist, which makes it a candidate for treating conditions related to inflammation and immune response. Research has explored its use in managing asthma, as it may help reduce bronchial hyperresponsiveness and inflammation in the airways. Additionally, Israpafant has been investigated for its potential benefits in treating septic shock, as it can inhibit the effects of PAF, a key mediator in the inflammatory cascade associated with this condition. Its anti-inflammatory properties also suggest possible applications in other inflammatory disorders, though further studies are needed to confirm its efficacy and safety in clinical settings.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
£0.00
£0.00
Total :